**ORIGINAL ARTICLE**

Interleukin33 deficiency causes tau abnormality and neurodegeneration with Alzheimer-like symptoms in aged mice

C Carlock¹, J Wu¹, J Shim¹, I Moreno-Gonzalez², MR Pitcher³, J Hicks⁴, A Suzuki⁵, J Iwata¹, J Quevado³,⁵ and Y Lou¹

Late-onset Alzheimer’s disease (AD) remains a medical mystery. Recent studies have linked it to impaired repair of aged neurons. Potential involvement of interleukin33 (IL33) in AD has been reported. Here we show that IL33, which was expressed by up to 75% astrocytes in the aged brains, was critical for repair of aged neurons. Mice lacking IL33 gene (Il33−/−) developed AD-like disease after 60–80 weeks, which was characterized by tau abnormality and a heavy loss of neurons/neurites in the cerebral cortex and hippocampus accompanied with cognition/memory impairment. We detected an abrupt aging surge in the cortical and hippocampal neurons at middle age (40 weeks). To counter the aging surge, wild-type mice rapidly upregulated repair of DNA double-strand breaks (DSBs) and autophagic clearance of cellular wastes in these neurons. Il33−/− mice failed to do so, but instead went on to develop rapid accumulation of abnormal tau, massive DSBs and abnormal autophagic vacuoles in these neurons. Thus, uncontrolled neuronal aging surge at middle age due to lack of IL33 resulted in neurodegeneration and late-onset AD-like symptoms in Il33−/− mice. Our study also suggests that the aging surge is a time to search for biomarkers for early diagnosis of AD before massive neuron loss.

*Translational Psychiatry* (2017) 7, e1164; doi:10.1038/tp.2017.142; published online 4 July 2017

**INTRODUCTION**

Late-onset Alzheimer’s disease (AD), which is an increasing socioeconomic burden worldwide, remains a medical mystery.¹ However, recent studies have linked this disease to the impairment in rejuvenation or repair of aged neurons.²–⁶ These mechanisms include DNA damage repairing and autophagic elimination of metabolic wastes.⁷–⁹ Neuron’s aberrant reentry into cell cycle in AD may de-regulate these mechanisms, resulting in neuron death.¹⁰ Deficiencies in cytokines or other immune molecules have also reportedly implicated in these rejuvenation mechanisms and neurodegenerative diseases including AD.¹¹–¹³ Expression of various cytokines such as IL-1β and TNFs in AD patients suggests their roles in AD pathogenesis.¹³,¹⁴ However, it remains to be determined if these cytokines may act as protective or inflammatory roles.

Interleukin33 (IL33), which is often detected as a nuclear protein, is a member of the interleukin1 cytokine family. It acts as mature cytokine after cleavage with ST2 as its receptor. Beyond its multifunction in immune defense, IL33 also plays a role in the injury healing in central nervous system and other diseases.¹⁵–¹⁹ IL33 has been genetically linked to human AD.²⁰ Injection of recombinant IL33 shows a beneficial effect in mouse AD models.²¹ Constitutive expression of IL33 in a wide range of tissues including the brain suggests its potential roles beyond immune defense.²²–²⁷ Our previous study has demonstrated one such role for IL33 in tissue homeostasis in degenerative ovarian tissue.²⁸–²⁹ In the present study, we investigated role of IL33 in tissue homeostasis in the brain. We found that IL33 was critical for repair of aged neurons. Its deficiency caused tau abnormality and late-onset of neurodegeneration in the cerebral cortex and hippocampus, accompanied with AD-like cognition and memory impairment.

**MATERIALS AND METHODS**

**Mice and their treatment**

C57BL/6 (B6) mice were purchased from Harlan (Indianapolis, IN, USA). Il33⁰/⁰ (WWW.KOMP.org) and Il33−/− mouse strain was created (WWW.KOMP.org) and characterized.²³,²⁴ The Il33−/− strain shows generally normal without any developmental defects.²⁵,²⁶ All animal procedures in this study were approved by institutional animal welfare committee. Mice were randomly selected for all experiments, and were tested with the group allocation blind to investigators; data were assembled after testing for each group for statistical analysis. Mice were perfused with room temperature PBS followed 2% paraformaldehyde before brains were harvested. In some cases, fresh brains were used.

**Histology and electron microscopy**

Brain tissues, fixed through perfusion, were embedded in paraffin and used for routine histology, including hematoxylin–eosin (H–E) staining, Bielschowsky silver staining and crystal violet staining. Three samples per group were processed for transmission electron microscopy following an established method.²⁹

**Behavioral tests**

Four behavioral tests were performed for assessment of cognition/memory impairment associated with AD in mice.³⁰–³² Locomotor activities

¹Department of Diagnostic Sciences, School of Dentistry, McGovern School of Medicine, University of Texas Health Science Center at Houston, Houston, TX, USA; ²Department of Neurology, McGovern School of Medicine, University of Texas Health Science Center at Houston, Houston, TX, USA; ³Department of Psychiatry and Behavioral Sciences, McGovern School of Medicine, University of Texas Health Science Center at Houston, Houston, TX, USA; ⁴Department of Pathology, Baylor College of Medicine, Houston, TX, USA and ⁵Laboratory of Neurosciences, Graduate Program in Health Sciences, Health Sciences Unit, University of Southern Santa Catarina, Criciúma, Brazil. Correspondence: Dr Y Lou, Department of Diagnostic Sciences, School of Dentistry, McGovern School of Medicine, University of Texas Health Science Center at Houston, Suite 5326 Behavioral and Biomedical Science Building, 1941 East Road, Houston, TX 77054, USA. E-mail: Yahuan.Lou@uth.tmc.edu

Received 12 May 2017; accepted 17 May 2017
(horizontal and vertical) test was performed in a computer-controlled activity cage (Ugo Basile, Monvalle, Italy) for an untrained mouse in the open testing chamber (54 × 50 × 37 cm) for recording its horizontal and vertical motions for 30 min. For habituation test, a mouse was placed in an open-field (60 × 40 cm) surrounded by 50 cm high plexi-glass wall, and allowed to explore freely for 5 min at day 1 and day 2 with numbers of its movements, that is crossing and rearing, recorded. Fear-based passive avoidance test was performed in Shocker-with-Scrambler behavioral chamber (PanLab, Barcelona, Spain). Mice received an electric shock (0.8 mA × 2 s) as training. The trained mice returned to the white chamber at day 1 and day 7 with their latency time for entering dark chamber (limited to 3 min) recorded. Rotarod performance test was carried out on an automatic instrument (Rotamex 4, Columbus Instrument, Columbus, OH, USA).

Bromodeoxyuridine incorporation test

Bromodeoxyuridine (BrDU; BD Biosciences, Franklin Lakes, NJ, USA) was dissolved in sterile DPBS at 10 mg ml⁻¹. Each mouse received intra-peritoneal injection of BrDUsolution at a dose of 1.5 mg per 25 g bodyweight in 150 μl of solution. The mice were killed 24 h later and perfused, and their brains or other tissues removed for detection of incorporated BrDUs by immunofluorescence using an anti-BrDu antibody.

Cerebral cortical homogenate, and fractionation of nuclei and organelles by gradient centrifugation

Fresh cortices were homogenized on ice in an extraction buffer containing a protease inhibitor cocktail (Sigma-Aldrich, St Louis, MO, USA). After centrifugation at 5000 g for 15 min at 4 °C, the supernatant was removed, and protein concentration measured. For nuclear fractionation, a published method with modifications was followed. Whole cortex was cut into 2 × 2 mm² in cold PBS, and gently homogenized in a glass homogenizer by Pestle (Wheaton Dounce tissue grinder, Millville, NJ, USA). Crude nuclear bodyweight in 150 μm sections were carried out at 4 °C. 20,000 r.p.m. for 4 h. Fractions recovered from interfaces of 10 Nycodenz (Sigma-Aldrich) discontinuous gradient (10, 20, 24, 26, 50%) at 35,000 g for 45 min. Each nuclear fraction was recovered from the interfaces: astrocyte nuclei on interface of 2.4 and 2.6 M, and neuronal nuclei 2.6 and 2.8 M. A small portion was used for microscopy to confirm the presence of neurons and astrocytes, and fractionation of autophagosomes, autolysosomes and lysosomes of cortical tissues. Whole cortical homogenate was centrifuged in a swing basket rotor at 53,500 g for 45 min. Each nuclear fraction was recovered from the interfaces: astrocyte nuclei on interface of 2.4 and 2.6 M, and neuronal nuclei 2.6 and 2.8 M. A small portion was used for microscopy to confirm the presence of neurons and astrocytes, and fractionation of autophagosomes, autolysosomes and lysosomes of cortical tissues.

Antibodies

Following antibodies were used in this study: biotin goat anti-mouse IL33, rat anti-mouse IL33, biotin rabbit anti- LC3, Alexa Fluor555 rabbit anti-LC3, rabbit anti-GFAP, mouse anti-tubulin β3, rabbit anti-BrDu, rabbit anti-PyH2AX, rabbit anti-ubiquitin, rabbit anti-amylloid β antibody, mouse anti-phospho-tau AT8, PHF1 and MC1, FITC-labeled anti-a-actin. Secondary reagents included Alexa-555, Alexa-594 and Alexa-647-labeled (Life Technologies, Carlsbad, CA, USA) and PE-labeled streptavidin. Biotin/avidin and anti-mouse CD16/32 were used for blocking non-specific IgG binding. Immunoglobulin isotypes were used as negative controls (BD Biosciences).

Western blot

Proteins were quantitated (Epoch GenS, BioTek, Winooski, VT, USA), and mixed at 1:1 with SDS sample buffer. Ten micromgs of protein were loaded on a SDS-polyacrylamide gel electrophoresis of various concentrations depending on size of target protein, and ran at a constant current. After transfer, the membrane (Immobilon-P PVDF, Millipore, Billerica, MA, USA) was used for immunostaining. Anti-a-actin mouse monoclonal antibody (AC-15, Sigma) was simultaneously added with the antibody to the target protein. The membrane was further incubated with IRDye 800CW-labeled secondary antibody for target protein and IRDye 680LT anti-mouse IgG antibody (LI-COR, Lincoln, NE, USA). The membrane was simultaneously scanned at both wave lengths on an infrared fluorescence scanner (Odyssey, LI-COR), with target protein as green and control a-actin as red.
exemplified by disappearance of both normal cortical layers and hippocampal apical dendrite tufts constituted by tubulin β3 in Il33−/− mice (Figures 2d and e, Supplementary Figures 1a and b). Quantitation showed that tubulin β3 density in Il33−/− mice reduced to 55% and 37% of the WT mice in the cortex and hippocampus, respectively (Figure 1f). Vacuoles were often observed in neuronal soma and neurites as early as 40 weeks (Figure 2g). Often open oval-shaped empty space was left after the loss of neurons (Figure 2g). These changes prompted us to test for any behavioral changes in Il33−/− mice. Increased locomotor activities are associated with murine AD.38,39 Il33−/− mice showed an age-related increase in locomotor activities especially after 60 weeks (Figure 3a, Supplementary Figure 1c). In habituation tests, old Il33−/− mice (60–80 weeks) did not display a decline in exploration activities post training as age-matched WT mice (Figure 3b). Fear-based passive avoidance test is often used to assess behavioral changes associated with AD or neurodegenerative diseases.40 This test revealed a significantly higher re-entry rate into the dark chamber post electric shock training in old Il33−/− mice, suggesting loss of short memory (Figure 3c). However, Il33−/− mice under 40 weeks did not show any behavioral changes as compared with WT mice (Figures 3a–c). Thus, Il33−/− mice began to develop cognition/memory impairments after 60–80 weeks. Interestingly, old Il33−/− mice showed no differences from age-matched WT mice in either motor function assessment or Purkinje cell density, suggesting that their cerebella were relatively unaffected (Figures 3d and e, Supplementary Figure 1d).

Il33−/− mice fail to repair stressed neurons after an abrupt aging surge at middle age

We next explored what had led to neurodegeneration in the cortex and hippocampus in old Il33−/− mice. We first detected an overwhelmingly large number of TUNEL+ nuclei in the cortex and hippocampus in aged Il33−/− mice (Figure 4a). Notably, ~90% of...
the cells in the dentate gyrus and CA region of hippocampus were TUNEL+. Co-staining with tubulin β3 revealed that the TUNEL+ cells were neurons (Figure 4b). Brain TUNEL+ neurons have been detected in human AD autopsy and animal models for neurodegenerative diseases.41,42 However, the nature of these TUNEL+ neurons remains ambiguous. We compared these TUNEL+ neurons with apoptotic ovarian cells during atresia of the same individuals.29 TUNEL intensity in neurons was only 1/20 to 1/40 of that of those apoptotic cells without any detectable caspases or DNA condensation (Supplementary Figures 2a and b). TUNEL can also detect genomic DNA double-strand breaks (DSBs). Thus, TUNEL+ in neuronal nuclei of Il33−/−mice indicated accumulation of a large number of DSBs. Whole-brain sections were scanned for calculating TUNEL density to quantitate DSBs. A rapid increase in

Figure 2. Il33−/− mice develop late-onset neurodegeneration and abnormal tau accumulation in the cerebral cortex and hippocampus. (a) Cortex and hippocampus from a representative 60-week Il33−/− mouse display neurodegeneration as compared to a wild-type (WT) mouse; enlarged boxed areas are shown below. Total seven mice for each group were examined with similar results. (b) Immunohistochemistry reveals heavy accumulation of paired helical fragment (PHF1) tau in cortical and hippocampal neurons in a representative 70-week Il33−/− mouse (n = 7). (c) Immunohistochemistry reveals cellular abnormal tau (AT8, PHF and insoluble tau MC1) in neurons. Arrows indicate neuron with MC1. (d) Silver stain of 30-μm section shows greatly reduced neurite networks in the cortex of a representative 70 weeks of Il33−/− mouse (n = 5) as compared to a WT littermate of the same age (n = 6). (e) Three-dimensional immunofluorescence on protein tubulin β3 reveals loss of neurite tufts of hippocampus in a 65-week Il33−/− mouse (n = 5) as compared to an age-matched WT mouse (n = 5). (f) Statistical summary of tubulin β3 area in WT and Il33−/− brains. (g) Crystal violet staining shows vacuoles in soma and axon of pyramid neurons (upper right), or empty spaces (arrow heads, lower right) in dentate gyrus of an Il33−/− mouse (n = 3). Note many neurons (arrows in lower left panel) are present in the same locations in a WT mouse. Bar unit = μm.
DSBs was observed in a 35–40-week window in Il33−/− brains (Figure 4c). The DSBs continued to increase with age thereafter, but at a slower rate. In contrast, only a few TUNEL+ cells were sporadically present in WT mice even after 60 weeks.

Oxidative stress may induce chronic neuronal death in AD.10,43,44 It causes apurinic/apyrimidinic (AP) site DNA lesion, but at a slower rate. In contrast, only a few TUNEL+ cells were observed at any ages in Il33−/− mice. Data are shown for each individual. (f) Western blot of cortical proteins also showed a rapid increase in DSB repairing in WT mice in the same cortex and hippocampus (Figures 4d–f), where TUNEL fluorescence detected PγH2AX+, but close to zero in Il33−/− mice (Figures 4d–f). When a DSB occurs, histone H2AX is phosphorylated by ATM, a key player for the formation of autophagosomes. LC3, a critical protein for the formation of autophagosomes, was reduced significantly in Il33−/− mice at 60 weeks with many of them double-membraned (Figure 5f and g). This suggests a failure in fusion efficiency has been linked to tau deposition and amyloid plaque.50,51 We studied nature of neuronal vacuoles (Figure 2e). Electron microscopy first showed accumulation of numerous vesicles or vacuoles in both neural soma and neurites of Il33−/− mice at 60 weeks with many of them double-membraned (Figure 5a, Supplementary Figure 2e). This indicates an abnormal accumulation of autophagosomes. LC3 and ubiquitinated proteins are often used as a measure for autophagy activities.52 LC3, a critical protein for the formation of autophagosomes, was reduced at 40 weeks prior to the onset of neuron loss in Il33−/− mice (Figures 5b and c). Decrease in autophagy was also evidenced by an increase in ubiquitinated proteins in Il33−/− mice (Figures 5d and e). However, reduced autophagic activities in Il33−/− mice could not explain the accumulation of autophagosomes in Il33−/− neurons. Cortical cells were fractionated into various organelles. A significantly lower quantity of autolysosomal LC3 was found in Il33−/− mice (Figures 5f and g). This suggests a failure in fusion between autophagosomes and lysosomes in Il33−/− neurons, leading to accumulation/aggregation of autophagosomes. Aggregated autophagosomes were detectable by immunofluorescence on LC3 in the neurons of Il33−/− mice after 40 weeks (Figure 5h). Thus, Il33−/− neurons also failed to complete autophagic digestion.

**DISCUSSION**

Current models for AD are largely transgenic animals, which overexpress mutant human amyloid precursor protein (APP), tau, or presenilin 1,53,54 Those models have shed light on the role of aggregation of tau or amyloid β in interference with essential cellular mechanisms. However, amyloid plaques and tau deposition in late-onset AD are not associated with mutations. Thus, cause of late-onset AD remains unclear. Mounting evidence suggests a critical role of abnormal neuronal aging in late-onset...
AD mice developed AD-like disease at old age due to impaired repair of aged neurons. Furthermore, the disease in our model resembles many pathological features of human late-onset AD. These shared features include late-onset neurodegeneration, heavy neuron loss in the cerebral cortex and hippocampus, tau abnormality and impaired cognition/memory at old age. Tau deposition is one of the most important hallmarks for human late-onset AD. To our knowledge, our model probably is the first one to show tau abnormality, which is unrelated to mutant tau genes. Although amyloid plaques were not present in Il33−/− mice, it is expected because murine APP lacks cleavage sites and hydrophobic residues for generating amyloid plaque.54

Neuronal aging process is also a result of accumulation of damaged molecules e.g. DSBs, reactive oxygen species and old.
Figure 5. Il33−/− mice fail to complete autophagic digestion in the neurons. (a) Electron microscopy reveals autophagic vesicles or vacuoles (arrows) in Il33−/− cortical neurons. Inset shows a double-membraned autophagic vesicle. Vacuoles are also present in neurites (arrowheads in rightmost panel). Three mice per group were observed with similar results. (b) Western blots detect reduced LC3 in cortical proteins. Each lane is for one individual. (c) Quantified IOD of LC3 I, LC3 II and α-actin bands in cortical proteins at 40 weeks. Ratios between total LC3 vs α-actin (left) and LC3 II vs LC3 I (right) are shown; n = 5. (d) Western blots reveal increased ubiquitinated proteins in the cortex of Il33−/− mice. Each lane is for one individual. (e) Quantified total IOD for ubiquitinated proteins and α-actin. Ratios between IODs of ubiquitinated proteins and α-actin of cortical proteins are shown for wild-type (WT) and Il33−/− mice at 40 weeks (n = 5) or 60–70 weeks (n = 5). (f) Western blot reveals a lower level of LC3 in autolysosomal fraction (arrowheads) in Il33−/− mice as compared to WT mice. Note that LC3 levels in other fractions were comparable to WT mice. Two representative sets of samples are shown for each group. Autolysosomes and autophagosomes were isolated from the cortex. (g) Ratio of IODs between autolysosomal and autophagosomal LC3 in WT and Il33−/− mice at 40 weeks. (h) Immunofluorescence shows LC3 aggregates (arrows in purple channel) in Il33−/− neurons, which are distinguishable from WT neurons by TUNEL+ (green) nuclei and diminished tubulin β3 (red); n = 3. IOD, integrated optical density.
organelles.47 Failed repair of DNA damage in aged neurons has been implicated in human AD.7–9 Our study revealed an abrupt aging surge in cortical and hippocampal neurons at middle-age (40-week) in mice. Failure in up-regulation of neuronal repair mechanisms to counter this aging surge in IL33/P47 mice may have led to chronic neuron death at old age. Therefore, neurodegeneration is initiated in IL33/P47 mice probably just after the aging surge. There are two significances for our discovery of the aging surge. First, neurodegeneration in IL33/P47 mice is due to uncontrolled aging surge. It can be considered an accelerated aging process in neurons. This accelerated aging process causes slow and chronic neuron death, which is well reflected by a long period of time between the aging surge at 40 weeks and heavy neuron loss/behavioral changes after 60–80 weeks. In fact, chronic neurodegeneration with a long asymptomatic period followed by a stage with mild clinical symptoms is an important hallmark for human AD.1 Second, human late-onset AD is often diagnosed when massive neuronal death has already occurred, and effective therapeutic intervention is impossible.1 Therefore, identification of biomarker for early diagnosis is a medical priority. If a neuronal aging surge at middle age (45–50 years) exists in humans, it will be then a promising time point to search for biomarkers for early diagnosis of AD long before massive loss of neurons. Our model will be a useful tool in exploring these biomarkers.

From this study, we are able to propose a hypothesis for cause of late-onset AD. The aging surge at middle age causes damages to neurons. Stressed neurons may signal surrounding astrocytes, which, in turn, cleave nuclear IL33 to release cytokine IL33. With ST2 as receptor, IL33 upregulates DSB repairing and autophagic digestion to ensure ‘rejuvenation’ of the aged neurons. Thus, deficiency in IL33 or its associated signal pathway impairs neuronal rejuvenation, leading to accumulation of DSBs and incomplete autophagy, which are known to accelerate aging process in neurons. Some studies also showed that defective autophagy is responsible for accumulation of abnormal tau and amyloid.50,51 As neurons are non-proliferative, rejuvenation of aged neurons is a prerequisite for a functional brain in elderly.41–43 Many studies have shown that repair of DNA damages and autophagic disposal of cellular wastes, for example, abnormal tau, are essential for neuronal rejuvenation.6–10,47 Failed repair of stressed neurons leads to neurodegeneration in the cortex and hippocampus after middle-age and subsequent AD-like dementia at old age. To test our hypothesis in future, we need to address several questions. First, how does IL33 regulate repair mechanisms in aged neurons? Although it still remains unclear, our study suggests that cytokine IL33 and its receptor ST2 may be involved, because of presence of cytokine IL33 in normal brains (Figure 1d) and expression of ST2 mRNA in the cortex and hippocampus but not in other regions at middle age (unpublished data). Recent studies also revealed roles of other cytokines in AD.14 It will be interesting to examine cross-talk among these cytokines. Second, whether the aging surge and IL33 also play roles in AD development in transgenic mice with WT human genes? It is worthwhile to mention that transgenic mice with WT human APP or tau do not develop AD-like disease or amyloid plaque/tau deposition.53–55 It will be very interesting to test whether IL33 deficiency in those transgenic mice will cause AD-like disease as well as amyloid plaques/tau deposition. In conclusion, our study revealed a critical role of IL33 in repair of stressed neurons especially in the cortex and hippocampus after an abrupt aging surge. IL33 deficiency leads to uncontrolled neuronal aging, which in turn causes tau abnormality, neurodegeneration and AD-like disease at old age.

CONFLICT OF INTEREST
The authors declare no conflict of interest.

ACKNOWLEDGMENTS
This work was supported by NIH R01DK077857 (to YL), NIH R01HD049613 (to YL), the institutional Translational Psychiatry Program (to JQ), grants from CNPq, FAPESC, Instituto Cérebro e Mente and UNESCO, Brazil (to JQ). We thank SL Huang, C Bales and WW Girdharan for technical assistance.

REFERENCES
1. Alzheimer’s Association. 2015 Alzheimer’s disease facts and figures. Alzheimers Dement 2016; 11: 332–384.
2. Nixon RA. The role of autophagy in neurodegenerative disease. Nat Med 2013; 19: 983–997.
3. Frake RA, Ricketts T, Menzies FM, Rubinstein DC. Autophagy and neurodegeneration. J Clin Invest 2015; 125: 65–74.
4. Coppede F, Migliore L. DNA damage and repair in Alzheimer’s disease. Curr Alzheimer Res 2009; 6: 36–47.
5. Anderson AJ, Su H, Cotman CW. DNA damage and apoptosis in Alzheimer’s disease: colocalization with c-Jun immunoreactivity, relationship to brain area, and effect of postmortem delay. J Neurosci 1996; 16: 1710–1719.
6. Suberbielle E, Djukic B, Evans M, Kim DH, Taneya P, Wang X et al. DNA repair factor BRCA1 depletion occurs in Alzheimer brains and impairs cognitive function in mice. Nat Commun 2015; 6: 8897.
7. Obulesu M, Rao DM. DNA damage and impairment of DNA repair in Alzheimer’s disease. Int J Neurosci 2010; 120: 397–403.
8. Hou Y, Song H, Croteau DL, Akbari M, Bohr VA. Genome instability in Alzheimer disease. Mech Ageing Dev 2017; 161: 83–94.
9. Malpass K. Alzheimer disease: DNA damage provides novel and powerful biomarkers of Alzheimer disease. Nat Rev Neuroal 2012; 8: 178.
10. Klein JA, Ackerman SL. Oxidative stress, cell cycle, and neurodegeneration. J Clin Invest 2003; 111: 785–793.
11. Ejlerskov P, Hultberg JB, Wang JY, Carlsson R, Ambjorn M, Kuss M et al. Lack of neuronal IFN-β-IFNAR causes Lewy Body- and Parkinson’s disease-like dementia. Cell 2015; 163: 324–329.
12. Vom Berg J, Prokop S, Miller KR, Obst J, Kälin RE, Lopategui-Cabezas I et al. Inhibition of IL-12/IL-23 signaling reduces Alzheimer’s disease-like pathology and cognitive decline. Nat Med 2012; 18: 1812–1819.
13. Zhang B, Gaiteri C, Bodea LG, Wang Z, McElwee J, Podtelezhnikov AA et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer’s disease. Cell 2013; 153: 707–720.
14. Morimoto K, Horio J, Satoh H, Sue L, Beach T, Anir A et al. Expression profiles of cytokines in the brains of Alzheimer’s disease (AD) patients compared to the brains of non-demented patients with and without increasing AD pathology. J Alzheimers Dis 2011; 25: 59–76.
15. Gadani SP, Walsh JT, Smiyov I, Zheng J, Kipnis J. The glia-derived alarmin IL-33 orchestrates the immune response and promotes recovery following CNS injury. Neuroin 2015; 85: 703–709.
16. Xi H, Katschke KJ Jr, Li Y, Truong T, Lee WP, Diehl L et al. IL-33 amplifies an innate immune response in the degenerating retina. J Exp Med 2016; 213: 189–207.
17. Jiang HR, Milovanovic M, Allan D, Niedbala W, Bensard AG, Fukada SY et al. IL-33 attenuates EAE by suppressing IL-17 and IFN-γ production and inducing alternative activated macrophages. Eur J Immunol 2012; 42: 1804–1814.
18. Stojanovic B, Milovanovic J, Arsenijevic A, Milovonic M, Arsenijevic N, Lukic ML. IL-33/ST2 axis mediates resistance to EAE by promoting regulatory B and tolerogenic dendritic cells. Neuroimmunol 2014; 275: 11–12.
19. Li M, Li Y, Liu X, Gao X, Wang Y. IL-33 blockade suppresses the development of experimental autoimmune encephalomyelitis in C57BL/6 mice. J Neuroimmunol 2012; 247: 25–31.
20. Chapuis J, Hot D, Hansmannel F, Kerdraon O, Ferreira S, Hubans C et al. Transcriptomic and genetic studies identify IL-33 as a candidate gene for Alzheimer’s disease. Mol Psychiatry 2009; 14: 1004–1016.
21. Fu AK, Hung K, Yuen MYF, Zhou X, Mak DSY, Chan ICW et al. IL-33 ameliorates Alzheimer’s disease-like pathology and cognitive decline. Proc Natl Acad Sci USA 2016; 113: E2705–E2713.
22. Wicher G, Husic E, Nilsson G, Forsberg-Nilsson K. Developmental expression of IL-33 in the mouse brain. Neurosci Lett 2013; 555: 171–176.
23. Xiong Z, Thangavel R, Kempuraj D, Yang E, Zaheer S, Zaheer A et al. IL-33 ameliorates IL-12/17-driven autoimmunity in a novel gene trap reporter strain. J Neuroin 2017; 188: 3488–3495.
Supplementary Information accompanies the paper on the Translational Psychiatry website (http://www.nature.com/tp)